Date | Time | Room | Session Title | Presentation Time | Topic | Role |
---|---|---|---|---|---|---|
20/05/2023 | 08:10 to 09:25 | Di Cavalcanti |
Medical Medical Hodgkin’s Lymphoma |
08:10 to 08:28 | How do I sequence new agents in first and second-line therapy for Hodgkin’s Lymphoma | Speaker |
20/05/2023 | 08:10 to 09:25 | Di Cavalcanti |
Medical Medical Hodgkin’s Lymphoma |
09:00 to 09:18 | Are we about to abandon transplantation in Hodgkin’s Lymphoma? | Speaker |
20/05/2023 | 08:10 to 09:25 | Di Cavalcanti |
Medical Medical Hodgkin’s Lymphoma |
08:28 to 08:35 | Q&A | Discussant |
20/05/2023 | 08:10 to 09:25 | Di Cavalcanti |
Medical Medical Hodgkin’s Lymphoma |
09:18 to 09:25 | Q&A | Discussant |
20/05/2023 | 12:00 to 15:00 | Di Cavalcanti |
Medical Medical Aggressive Lymphomas |
12:50 to 13:08 | Moving beyond CHOP/CHOEP: How disease features can guide treatment in T-cell lymphomas | Speaker |
20/05/2023 | 12:00 to 15:00 | Di Cavalcanti |
Medical Medical Aggressive Lymphomas |
14:30 to 15:00 | Round table: how to extract the best from conjugated or unconjugated monoclonal antibodies, chemotherapies, bispecific antibodies, and CAR-T in lymphomas? | Discussant |
20/05/2023 | 12:00 to 15:00 | Di Cavalcanti |
Medical Medical Aggressive Lymphomas |
13:08 to 13:15 | Q&A | Discussant |